Applying an Equity Lens to Pediatric Obesity

Pediatric Clinics of North America, Journal Year: 2024, Volume and Issue: 71(5), P. 805 - 818

Published: Aug. 8, 2024

Language: Английский

---

Treatment of obesity in US children and adolescents before and after the AAP guidelines

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 28, 2024

Abstract Importance The American Academy of Pediatrics (AAP) published new comprehensive guidelines for childhood obesity treatment, including pharmacotherapy. However, changes in treatment patterns following these remain unknown. Objective To assess and adolescent the AAP guidelines. Design Using Truveta electronic health record (EHR) data, this cohort study analyzed outpatient visits between January 2021 June 2024 children (age 8-11) adolescents 12-17) with no evidence type 2 diabetes (T2D). For patients multiple visits, one visit was randomly selected. Patients without a recent history specific treatments were followed at or their visit, nutrition referral within 14 days counseling 90 days, and, separately, pharmacotherapy prescriptions weight management (on- off-label) days. Interrupted time series models used to compare differences before versus after released. Setting Clinical prescribing data from EHRs collective US systems. Participants 329,357 aged 8 17 an office BMI percentile indicating obesity, T2D diagnosis. Exposure Release 2023. Main Outcomes Measures Evidence eligible (1) counseling, (2) Results population 329,581 included 120,734 (36.6%) 208,847 (63.4%) adolescents. mean (SD) 97.4 (1.6), 119,864 (36.4%) having severe (class 3). Overall, minority had (4.0%) (0.4%) during shortly visit. Following guidelines, indicators both immediate (odds ratio [95% CI]: 1.38 [1.08-1.75]) gradual monthly (1.06 [1.04-1.08]) observed use. An change (1.34 [1.24-1.45]), but additional (1.0 [0.99-1.01]). Conclusions Relevance While use increased, overall rates remained low.

Language: Английский

---

Longitudinal policy surveillance of state obesity legislation in California, 1999–2020

BMC Public Health, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 6, 2024

Abstract Background Obesity rates among children and adults continue to accelerate in the U.S., particularly marginalized low-income populations. prevention reduction policies can significantly impact population health by improving environmental conditions increasing access health-promoting resources. Limited research has been conducted examine state obesity policy change over time. The primary aim of this study is legislative approaches used prevent reduce California (U.S.). Methods We quantitative surveillance methods develop a database obesity-related legislation (bills, resolutions) introduced California’s legislature between 1999 2020. Descriptive statistics were trends enacted characteristics. Chi-square tests determine differences characteristics non-enacted legislation. Legislative session found be associated with enactment predict adoption logistic regression. Results A total 284 bills resolutions 2020 peak 43 2005–2006. On average, 25.8 each 2-year cycle. Findings indicate that (a) schools most frequently specified setting; (b) common topics nutrition (45%) physical activity (33%); (c) only 15% mentioned race/ethnicity. Overall, 24.9% compared 82.1% adopted. Legislation raise awareness about had 5.4 times odds being passed other topics. Yet difference was not statistically significant sensitivity analysis when we excluded resolutions. Conclusions This leveraged advance our knowledge effective equitable instruments obesity. reveal important elements may success, including topic, contribute nascent evidence base for public law research, legal epidemiology, practice. Future work should investigate role effectiveness on policymaking.

Language: Английский

---

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Journal of Pharmaceutical Policy and Practice, Journal Year: 2024, Volume and Issue: 18(1)

Published: Dec. 24, 2024

Background High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists weight loss in United States. This has not been systematically studied. We conducted pilot study assess prevalence, characteristics, advertising content direct-to-consumer providers products Colorado.

Language: Английский

---

Anti-obesity medication patients’ self-reported food savings versus the cost of such medicines

International Journal of Obesity, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 29, 2024

Language: Английский

---